Wall Street analysts forecast KPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KPRX is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast KPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KPRX is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.300
Low
12.00
Averages
12.00
High
12.00
Current: 2.300
Low
12.00
Averages
12.00
High
12.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$10
2025-07-22
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$10
AI Analysis
2025-07-22
maintain
Buy
Reason
H.C. Wainwright reiterates a Buy rating and $10 price target on shares of Kiora Pharmaceuticals after the company announced that it received received a U.S. patent covering KIO-104 for the treatment of ocular diseases, including ocular inflammation, uveitis, age-related macular degeneration, and complications from refractive surgery. The patent covers varying dosing schedules, necessary excipients, and other novel methods for optimizing treatment of ocular inflammatory diseases, the analyst tells investors in a research note. The new patent should strengthen the company's IP portfolio and help secure the potential market prospects if KIO-104 is successfully developed in clinical studies, the firm says.
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$10
2025-03-28
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$10
2025-03-28
Reiterates
Strong Buy
Reason
About KPRX
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders
Oct 30 2025PRnewswire
Kiora Pharmaceuticals Joins RARE-X Vision Consortium: Kiora Pharmaceuticals has partnered with Global Genes to join the RARE-X Vision Consortium, aimed at enhancing collaboration among stakeholders to develop therapies for rare ocular disorders.
Goals of the Vision Consortium: The consortium focuses on patient identification, recruitment, and developing meaningful outcome measures for clinical trials, while integrating patient voices into study designs to improve the lives of those affected by rare vision disorders.
Continue Reading
HC Wainwright & Co. Reiterates Buy on Kiora Pharmaceuticals, Maintains $10 Price Target
Mar 28 2025Benzinga
Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.
Continue Reading
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?
How does the company's performance compare to its main competitors in the same sector?
